Amgen Inc. (NASDAQ:AMGN) Stock Holdings Trimmed by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 12.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 670,995 shares of the medical research company’s stock after selling 92,822 shares during the quarter. New York State Common Retirement Fund’s holdings in Amgen were worth $216,201,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC bought a new stake in Amgen during the second quarter valued at $26,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC acquired a new stake in Amgen during the second quarter worth about $33,000. Finally, Matrix Trust Co bought a new position in Amgen in the third quarter worth about $36,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AMGN. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. Sanford C. Bernstein started coverage on shares of Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Finally, UBS Group cut their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Price Performance

NASDAQ:AMGN traded down $0.68 during mid-day trading on Friday, reaching $319.48. 109,851 shares of the stock were exchanged, compared to its average volume of 2,409,992. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The firm has a market capitalization of $171.67 billion, a PE ratio of 40.99, a PEG ratio of 2.84 and a beta of 0.61. The business has a fifty day moving average price of $324.66 and a 200 day moving average price of $314.82.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 181.58%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 EPS. Research analysts expect that Amgen Inc. will post 19.48 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.